Background {#Sec1}
==========

*Cellulosimicrobium* species are gram-positive bacilli belonging to the order *Actinomycetales*. Formerly known as *Oerskovia,* they were reclassified in 2001 as *Cellulosimicrobium* by Schumann et al. \[[@CR1]\]. The genus comprises various species \[[@CR2]\], but only two have been described as pathogens in humans: *C. cellulans*, formerly known as *Oerskovia xanthineolytica*, and *C. funkei*, formerly *Oerskovia turbata*. They are widely distributed in the environment and have been isolated mainly from soil, water, and grass cuttings \[[@CR3]\]. Despite this ubiquitous distribution, *Cellulosimicrobium* species rarely cause infections in humans. Here, we report a case of prosthetic infective endocarditis (IE) caused by *C. cellulans* and present a complete literature review of infections caused by these organisms, in order to improve our knowledge of this unusual infection.

Case presentation {#Sec2}
=================

An 82-year-old woman with type 2 diabetes mellitus and chronic renal failure was admitted to the hospital with a 7-day history of fever, delirium, and dyspnea. She had undergone an aortic valve replacement (Perceval sutureless bioprosthesis) 18 months prior due to aortic stenosis. The immediate post cardiac surgery period was complicated by paroxysmal atrial fibrillation, transudative left-sided pleural effusion, and oligoanuric renal failure. She did not present any infectious complications and the median sternotomy incision closed normally. Between 1 and 14 months after aortic surgery, she was admitted to the hospital five times because of severe clinical heart failure of unclear cause and some episode of paroxysmal atrial fibrillation. No fever or other signs of infection were detected at all this time, and did not receive any antibiotic treatment. A transesophageal echocardiogram performed 3 months after surgery showed an aortic prosthesis without alterations. On physical examination, her temperature was 39 °C, she was confused and tachypneic. A 3/6 systolic ejection murmur in the aortic position and basal crackles were identified. She presented grade II uninfected pressure ulcers on heels and sacrococcygeal region. Laboratory tests showed a normal blood cell count, a serum creatinine of 2.14 mg/dL, and an increased C-reactive protein (13 mg/dL) and hyperglycemia (628 mg/dL). A chest X-ray showed bilateral pleural effusion and interstitial pulmonary edema. Two sets of aerobic and anaerobic blood culture bottles were drawn at admission, and empiric ceftriaxone (2 g daily) and levofloxacin adjusted to renal function (250 mg daily, intravenous) were started. After 26 to 80 h of incubation into the BACTEC FX system (Becton, Dickinson and Company), all four blood culture bottles were positive. Gram stain showed coryneform gram-positive bacilli with occasional branching forms. After incubation on CNA agar and chocolate agar, colonies were less than 2 mm in size, glistening and yellow. The colonies penetrated into the agar upon further incubation. On the 5th day of admission, blood cultures were again obtained, and the same organism grew in 1 of the 4 bottles. The isolates were initially identified by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS, Bruker Daltonics) as *C. cellulans*. Thereafter, the identification was confirmed by API Coryne strip (bioMérieux; code number 7572767), which was an "excellent identification" for *C. cellulans* with a reliability of 99.9%, and by sequencing the 16S rRNA (using the BLAST Sequence Analysis Tool of GenBank database), showing a 100% similarity with *C. cellulans* and 99.8% with *C. funkei*. Antimicrobial susceptibility tests were performed using a microdilution microtiter panel MICroSTREP plus 6 (MicroScan Walk Away, Beckman Coulter). Following EUCAST breakpoints criteria for *Corynebacterium*, the isolate was susceptible or presumably susceptible (for antibiotics without EUCAST breakpoints, but with low MIC) to amoxicillin-clavulanate (MIC = 2 mg/L), daptomycin (MIC = 0.5 mg/L), levofloxacin (MIC = 2 mg/L), linezolid (MIC≤1 mg/L), tetracycline (MIC≤1 mg/L), trimethoprim-sulfamethoxazole (MIC = 0.006 mg/L) and vancomycin (MIC = 0.5 mg/L), and resistant or presumably resistant to amikacin (MIC = 32 mg/L), cefotaxime (MIC\> 2 mg/L), ciprofloxacin (MIC\> 2 mg/L), clindamycin (MIC\> 2 mg/L), erythromycin (MIC = 1 mg/L), gentamycin (MIC = 4 mg/L), imipenem (MIC = 4 mg/L), meropenem (MIC = 8 mg/L) and rifampin (MIC = 1 mg/L). The MICs of amoxicillin-clavulanate, cefotaxime, meropenem, trimethoprim-sulfamethoxazole and vancomycin were also determined by Etest® (bioMérieux) using Mueller-Hinton agar plus 5% blood, and similar results were found.

On the 7th day, a transthoracic echocardiogram did not show alterations. Therapy was switched to amoxicillin-clavulanate (1 g three times daily, intravenous), and new blood cultures obtained 24 h later were negative. A transesophageal echocardiogram performed on the 9th day of stay revealed an echogenic and mobile vegetation of 6 × 9 mm on the prosthetic aortic valve attached to the commissure between the right coronary cusp and the non-coronary cusp. Prosthetic valve function was otherwise normal. On the 11th day, amoxicillin-clavulanate was switched to vancomycin adjusted to renal function (750 mg daily) plus linezolid (600 mg twice daily, intravenous). Surgical replacement was considered inappropriate in this patient due to comorbidity, advanced age, limited mobility and family rejection. In the following days, she developed severe anemia, acute confusional state and refractory heart failure. End-of-life decision-making was implemented, prioritizing symptom control, and antibiotic therapy was switched back to amoxicillin-clavulanate on day 22nd of admission. On the 28th day, she was discharged to another hospital for palliative care, dying 7 days later because of sepsis and severe heart failure. A postmortem examination was not performed.

Method {#Sec3}
======

We searched MEDLINE using the following keywords: "*Cellulosimicrobium*", "*C. cellulans*", "*C. funkei"*, "*Cellulosimicrobium* species", "*Oerskovia"*, "*O. xanthineolytica"*, "*O. turbata"*, and "*Oerskovia* species". The search period was from 1970, the year in which the *Oerskovia* genus was first described \[[@CR4]\], until March 2019. The reference lists of identified articles were also reviewed to find additional cases. No language restrictions were applied. We excluded from this analysis one of the cases published by Funke and Marty \[[@CR5]\] because the authors interpreted isolation as a contaminant, as well as a series of 35 clinical isolates of *Oerskovia* species \[[@CR6]\] because the corresponding clinical data was not available.

Discussion and conclusions {#Sec4}
==========================

*Cellulosimicrobium* species are gram-positive bacilli belonging to the order *Actinomycetales*, suborder *Micrococcineae*, family *Promicromonosporaceae*. They are organisms that have undergone several taxonomic changes. *Oerskovia xanthineolytica*, described in 1972 \[[@CR3]\], was reclassified in 1982 as *Cellulomonas cellulans* \[[@CR7]\]. In 2001, Schumann et al. \[[@CR1]\] proposed its reclassification in a new genus, *Cellulosimicrobium*, and *Oerskovia xanthineolytica* was renamed as *Cellulosimicrobium cellulans*. The rationale for this proposal was the distinct position of this species on the neighbour-joining phylogenetic tree, based on 16S rRNA gene sequencing, and the presence of unique peptidoglycan in the cell wall, which was absent from authentic *Cellulomonas* species. The genus comprised only the type species *C. cellulans* until 2006, when Brown et al. \[[@CR8]\] proposed that some clinical isolates identified in 1970 as *Oerskovia turbata* \[[@CR4]\] be included in this genus as a new species, *Cellulosimicrobium funkei*.

A total of 43 cases of infections caused by *Cellulosimicrobium* (or *Oerskovia*) were identified in the literature review. They are summarized in Table [1](#Tab1){ref-type="table"} \[[@CR5], [@CR9]--[@CR47]\]. There were 25 (58%) males, and the median age was 49 years (range 0--81 years). Seven (16%) were children. Forty cases were sporadic infections and 3 were associated with an outbreak of endophthalmitis after cataract surgery at a hospital in Turkey \[[@CR42]\]. Most of the cases were from the USA (*n* = 18) and Spain (*n* = 6), and almost half were published in the last 15 years. Twenty-six (60%) patients suffered from a variety of chronic underlying illnesses that involved immune dysfunction. The most frequent were chronic kidney failure (8 cases, 5 of them on peritoneal dialysis, 1 on hemodialysis, and 1 a renal transplant patient), diabetes mellitus (4 cases), solid organ neoplasia (4 cases), neutropenia (4 cases), hematologic malignancies (3 cases, 2 of them with bone marrow transplant), HIV infection (3 cases), alcoholism (2 cases), and inflammatory bowel disease (2 cases). Table 1Reported cases of *Cellulosimicrobium* species (or *Oerskovia*) infectionsRefAge/sexPredisposing condition or underlying diseaseSpecies (specimen)Type of infectionForeign body (time before)/ removalAntibiotic therapy^a^ and surgeryFailed antibiotic therapy alone^b^Outcome\[[@CR9]\]68 yr./MAortic insufficiency, prosthetic valve, Crohn's, ankylosing spondylitis, steroids*O. turbata* (blood, prosthetic heart valve)EndocarditisProsthetic heart valve (2 mo)/yesPEN, AMP + ERY, SXT, SXT + AMP, SXT + AMXAortic valve replacementYesCure\[[@CR10]\]3 yr./MAcute myelogenous leukemia, neutropenia*O. turbata* (blood)CVC-related bacteremiaCVC (1 mo)/yesAMKYesCure\[[@CR11]\]40 yr./FCrohn's, short bowel syndrome*Oerskovia* species (blood, TPN solution)CVC-related bacteremiaCVC (9 mo)/noVAN+GEN + MET, VANNoCure\[[@CR12]\]40 yr./MAlcoholism, cirrhosis*O. xanthineolytica* (blood)BacteremiaNoneVAN+GEN + CLINACure\[[@CR13]\]54 yr./FMetastatic breast cancer, chemotherapy*O. xanthineolytica* (blood)CVC-related? bacteremiaCVC (4 mo) (unclear role)/noCXM, VANNoCure\[[@CR14]\]49 yr./FMetastatic colonic cancer*O. xanthineolytica* (blood, CVC tip)CVC-related bacteremiaCVC (15 mo)/noVANNoCure\[[@CR15]\]27 yr./MAIDS, neutropenia*O. turbata* (blood)CVC-related bacteremiaCVC (4 wk)/yesIMP+AMKNACure\[[@CR16]\]53 yr./FNon-Hodgkin's lymphoma, BMT, neutropenia*O. xanthineolytica* (blood, CVC tip)CVC-related bacteremia ➔EndocarditisCVC (1 yr)/yesDOX, CLI, MPM, AMX + SXT, IMP+AMK, CLA + RIF, PENNADeath\[[@CR17]\]64 yr./FPeritonitis carcinomatosa*O. xanthineolytica* (blood)BacteremiaNonePTZ, PTZ + NET, VAN+NET, PTZ + NETNACure\[[@CR18]\]31 yr./MCRF, renal transplant, DM*O. xanthineolytica* (blood, heart valve)CVC-related bacteremia ➔EndocarditisCVC (NR)/yesAMS, AMS + VAN, CAZ + VAN, VANAortic valve replacementNACure\[[@CR19]\]13 yr./MShort bowel syndrome*C. cellulans* (blood)CVC-related bacteremiaCVC (NR)/noVAN+CTX, VAN+GEN, VAN, VAN+RIFNoCure\[[@CR20]\]1 d/MNone*C. cellulans* (blood)BacteremiaNoneCTX + AMP, VANNACure\[[@CR21]\]81 yr./MAortic stenosis, prosthetic valve*C. funkei* (blood)EndocarditisProsthetic heart valve(7 mo)/noAMC, VAN+GENYesDeath\[[@CR22]\]59 yr./MCOPD, arteriosclerosis*C. cellulans* (blood)CVC-related bacteremiaCVC (7 d)/yesVAN+PTZNADeath\[[@CR23]\]80 yr./FCRF, hemodialysis*C. cellulans* (blood)CVC-related bacteremiaCVC (NR)/yesVANYesCure^*c*^\[[@CR24]\]59 yr./FMetastatic rectal cancer*C. cellulans* (blood)CVC-related bacteremiaCVC (NR)/yesVAN, VAN+IMP, VANYesCure\[[@CR25]\]44 yr./FT-cell lymphoma, BMT, neutropenia*Cellulosimicrobium* species (blood, CVC tip)CVC-related bacteremiaCVC (5 wk)/yesVAN+CPM, VAN+MPM, VANNADeath\[[@CR26]\]≈50 yr./MDM*Oerskovia* species (blood)OsteomyelitisNoneVAN+CPM + MET, SXTAmputationNACure\[[@CR27]\]47 yr./FKidney trouble?*Oerskovia* species (kidney)PyonephrosisNoneNephrectomyNACure\[[@CR28]\]47 yr./MPenetrating eye injury, steroids*O. xanthineolytica* (vitreous humor)EndophthalmitisIntraocular metallic object (12 d)/yesGEN (sc), PEN, PEN+CFLVitrectomyNACure\[[@CR29]\]38 yr./FHydrocephalus*O. xanthineolytica* (CSF)MeningitisVP shunt (7 yr)/yesPEN, PEN+RIFYesCure\[[@CR30]\]70 yr./MCRF, CAPD*O. xanthineolytica* (peritoneal fluid, PC tip)PeritonitisPC (11 yr)/yesVAN+GENYesCure\[[@CR31]\]23 yr./MAIDS*O. turbata* (subcutaneous fluid)Soft tissue infectionNoneDebridementNACure\[[@CR5]\]53 yr./FArthropathy, intramuscular injections*O. xanthineolytica* (subcutaneous fluid)Soft tissue infectionNoneDOXNACure\[[@CR5]\]72 yr./MNone*O. xanthineolytica* (bile)CholecystitisNoneCFXCholecystectomyNACure\[[@CR32]\]59 yr./FCRF, CAPD, DM*O. xanthineolytica* (peritoneal fluid)PeritonitisPC (6 wk)/noVAN (ip) + TOB, DOXNoCure\[[@CR33]\]28 yr./FNone*O. xanthineolytica* (cornea)KeratitisContact lens (NR)/yesCFZ (drops) + GEN (drops)NACure\[[@CR34]\]72 yr./MGonarthrosis, knee prosthesis, closed knee injury, alcoholism*O. xanthineolytica* (sinovial tissue, bone)Prosthetic joint infectionProsthetic joint (3 yr)/yesVAN, SXTTwo-stage reimplantationNACure\[[@CR35]\]13 yr./FCRF, CAPD*O. xanthineolytica* (peritoneal fluid)PeritonitisPC (11 mo)/noVAN (ip)NoCure\[[@CR36]\]23 mo/FNone*O. xanthineolytica* (intervertebral biopsy)SpondylodiscitisNoneCFT + RIF, CXM + RIFNACure\[[@CR37]\]48 yr./MHIV*C. cellulans* (ulcer)Tongue ulcerNonePEN+AZINACure\[[@CR38]\]44 yr./MHydrocephalus*O. xanthineolytica* (CSF, VP shunt)MeningitisVP shunt (3 mo)/yesVAN+RIFYesCure\[[@CR39]\]76 yr./MCOPD*O. turbata* (bile)CholecystitisNoneCholecystectomyNACure\[[@CR40]\]5 yr./MPenetrating hand injury*C. cellulans* (tendon, deep biopsy)TenosynovitisSplinters (4 mo)/yesSXT + RIFDebridementNACure\[[@CR41]\]1 d/MPremature*O. xanthineolytica* (lung)PneumoniaNoneCTX + GENNADeath\[[@CR42]\]72 yr./FCataract surgery*C. cellulans* (vitreous humor)EndophthalmitisIntraocular lens (1 d)/noVAN (iv) + CAZ (iv)NoCure\[[@CR42]\]74 yr./MCataract surgery, arteriosclerosis*C. cellulans* (vitreous humor)EndophthalmitisIntraocular lens (3 d)/noVAN (iv) + CAZ (iv)NoCure\[[@CR42]\]78 yr./FCataract surgery*C. cellulans* (vitreous humor)EndophthalmitisIntraocular lens (7 d)/noVAN (iv) + CAZ (iv)VitrectomyNoCure\[[@CR43]\]28 yr./MPenetrating eye injury*C. cellulans* (vitreous humor)EndophthalmitisIntraocular metallic object (2 d)/yesVAN+CAZ + CLI, VAN+CAZ + MOX (all iv)VitrectomyYesCure\[[@CR44]\]45 yr./MNone*C. cellulans* (vitreous humor)EndophthalmitisNoneCIP, VAN (iv) + CAZ (iv)VitrectomyNACure\[[@CR45]\]62 yr./MCRF, CAPD*O. turbata* (peritoneal fluid)PeritonitisPC (3 yr)/yesVAN (ip) + GEN (ip) + CIP, VAN (ip) + SXT, VAN (ip) + GEN (ip) + SXT, VAN (ip)YesCure\[[@CR46]\]81 yr./MCRF, penetrating knee injury*C. cellulans* (sinovial fluid)ArthritisNoneLEV, LEV+LNZ, LNZ + RIFDebridementNACure\[[@CR47]\]50 yr./FCRF, CAPD, DM*C. cellulans* (peritoneal fluid, PC tip)PeritonitisPC (15 mo)/yesCAZ (ip) + TOB (ip), CAZ (ip) + TOB (ip) + VAN (ip), VANYesCure*AIDS* Acquired immunodeficiency síndrome, *AMC* Amoxicillin-clavulanate, *AMK* Amikacin, *AMP* Ampicillin, *AMS* Ampicilllin-sulbactam, *AMX* Amoxicillin, *AZI* Azithromycin, *BMT* Bone marrow transplant, *CAPD* Chronic ambulatory peritoneal dialysis, *CAZ* Ceftazidime, *CFL* Cephalexin, *CFT* Ceftriaxone, *CFX* Cefoxitin, *CFZ* Cefazolin, *CIP* Ciprofloxacin, *CLA* Clarithromycin, *CLI* Clindamycin, *COPD* Chronic obstructive pulmonary disease, *CPM* Cefepime, *CRF* Chronic renal failure, *CSF* Cerebrospinal fluid, *CTX* Cefotaxime, *CVC* Central venous catheter, *CXM* Cefuroxime, *DM* Diabetes mellitus, *DOX* Doxycycline, *ERY* Erythromycin, *GEN* Gentamycin, *HIV* Human immunodeficiency virus, *IMP* Imipenem, *ip* Intraperitoneal, *iv* Intravitreal, *LEV* Levofloxacin, *LNZ* Linezolid, *MET* Metronidazole, *MOX* Moxifloxacin, *MPM* Meropenem, *NA* Not applicable, *NR* Not reported, *NET* Netilmicin, *PC* Peritoneal catheter, *PEN* Penicillin, *PR* Present report, *PTZ* Piperacillin-tazobactam, *RIF* Rifampin, *sc* Subconjunctival, *SXT* Trimetroprim-sulfamethoxazole, *TOB* Tobramycin, *TPN* Total parenteral nutrition, *VAN* Vancomycin, *VP* Ventriculoperitoneal^a^The route of administration is systemic if it is not specified^b^That is, foreign body associated infections which were not cured by antibiotic therapy alone (10 cases requiring its removal and another case resulting in death)^c^Later death not attributable to the infection

Infection was related to the presence of medical devices or foreign bodies in 29 (67%) cases, mainly with central venous catheter (CVC) (*n* = 12) causing CVC-related bacteremia, but also with peritoneal catheters, intraocular lenses, cardiac valve or joint prostheses, or ventriculo-peritoneal shunts. Moreover, spontaneous infections have also been reported, including primary bacteremia, pneumonia, cholecystitis, pyonephrosis, endophthalmitis, soft tissue infection, arthritis and osteomyelitis. Of all the 43 cases, 7 (16%) were either non-immunocompromised patients or non-carriers of foreign bodies. Our review shows 4 previous cases of IE corresponded to 2 cases with early prosthetic aortic IE by the currently named *C. funkei* (one of them as a result of implanting a contaminated prosthesis) diagnosed respectively 2 and 7 months after cardiac surgery, and 2 cases with native IE by the current *C. cellulans* (both secondary to CVC-related bacteremia). Thus, the patient presented herein is the first with prosthetic IE due to *C. cellulans*. The pathogenesis of the infection in our patient can be debatable. After cardiac surgery, she presented a torpid evolution with several hospital admissions, but had no infectious complications related to any medical procedure, signs of cutaneous infection in pressure ulcers and the onset of symptoms was not associated to any possible inoculation procedure. Without being able to completely exclude a hematogenous spread to the prosthetic valve, we believe that in the absence of another source of infection it is more reasonable to think of a late presentation (or late diagnosis) of a periprosthetic valve infection. Many of *Actinomycetales* infections are characterized by a relatively long history with minimal clinical signs of infection at initial presentation, which often leads to a delay in diagnosis. The diagnosis of IE in our patient was based on the Duke clinical criteria, as no pathological specimens were available. Bacterial identification was performed by MALDI-TOF MS and was confirmed at least to the genus level by the API Coryne system and the 16S rRNA sequencing. They are reliable techniques that have been used for the bacterial identification in many of the reported cases \[[@CR5], [@CR13], [@CR15]--[@CR17], [@CR19]--[@CR25], [@CR34], [@CR35], [@CR37], [@CR40]--[@CR42], [@CR44]--[@CR47]\]. However, the API Coryne system and the 16S rRNA sequencing may not be able to distinguish between the two species with absolute certainty \[[@CR21]\]. As these organisms can very easily be confused by its appearance with *Corynebacterium* species, they can be disregarded as contaminants if microbiologic identification is incomplete. A full microbiological identification must be attempted at least to the genus level when coryneform gram-positive bacilli are isolated in this patient population.

Given the rarity of this infection, there are no standardized recommendations for the treatment of infections caused by *Cellulosimicrobium* species. It is difficult to draw conclusions from the reviewed cases concerning the real effectiveness of the antibiotic regimens because the antimicrobial agents used were not homogeneous, the duration of therapy varied and was not always specified, and as in our case there were frequent changes in antibiotic therapy in many of them. Table [2](#Tab2){ref-type="table"} shows the antimicrobial susceptibility data of *Cellulosimicrobium* species, taken from the cases reviewed. Based on these in vitro results, vancomycin and linezolid would be considered the drugs of choice. However, this should be interpreted with caution due to the fact that there are no standardized methods or interpretation breakpoints for this organism. Thus, the methods used and the interpretation criteria, data available in 19 of the reviewed cases, were variable (mainly disk diffusion and microdilution). Antibiotic therapy was administered to 40 patients. Twenty-six patients were treated with vancomycin, either as single-agent therapy (*n* = 6) or in combination therapy (*n* = 20), and as first-line therapy (*n* = 19) or as follow-up therapy (*n* = 7). We observed that the mortality rate was similar between patients with or without vancomycin on the antibiotic regimen. Only one patient was treated with linezolid and it is not possible to assess the clinical efficacy of this drug. There is no clinical experience nor data on their in vitro activity in the cases reviewed in this study with more recent antibiotics such as daptomycin or the new glycopeptides. In our case, it was presumed that the isolated bacteria was susceptible in vitro to daptomycin. The broad spectrum of activity of these 'new' antibiotics against gram-positive bacteria, including different *Actinobacteria*, suggests that these antibiotics could be a therapeutic alternative. Table 2Antibiotic susceptibility data of *Cellulosimicrobium* species (or *Oerskovia*) in reported casesAll species*C. cellulansC. funkei*No. of isolatesMIC range (mg/L)% SusceptibilityNo. of isolates% SusceptibilityNo. of isolates% SusceptibilityAMC41/0.5--16/850%450%----AMK114--1673%757%3100%CFZ91--867%875%----CIP151 - \> 813%1217%00%CLI132--88%120%----CTX78--6429%520%250%ERY191--1626%1315%450%GEN142--1643%911%4100%IMP8\<  0.25 - \> 1675%683%250%LNZ40.5--1100%4100%----PEN240.012--425%1718%425%RIF12\<  0.5--475%978%367%SXT20\<  0.06/1.19--8/15285%1593%450%TET161--850%1354%250%VAN30≤ 0.25 - \< 4100%23100%5100%*AMC* Amoxicillin-clavulanate, *AMK* Amikacin, *CFZ* Cefazolin, *CIP* Ciprofloxacin, *CLI* Clindamycin, *CTX* Cefotaxime, *ERY* Erythromycin, *GEN* Gentamycin, *IMP* Imipenem, *LNZ* Linezolid,*MIC* Minimum inhibitory concentration, *PEN* Penicillin, *RIF* Rifampin, *SXT* Trimetroprim-sulfamethoxazole, *TET* Tetracycline, *VAN* Vancomycin

In addition to antibiotic therapy, debridement of infected tissue in localized infections and foreign bodies removal in the infections associated with them were usually required for complete recovery. Nineteen of the 29 patients with foreign body associated infections were treated with foreign body removal and 16 achieved cure. This includes 10 patients with persistence or recurrence of infection despite the use of active antibiotic therapy until the foreign body was finally removed. In all 10 patients treated without foreign body removal, the antibiotic regimen included vancomycin, and a recovery with complete eradication of the pathogen was obtained in 9 patients. Thus, treatment with antibiotics alone failed in 38% (11/29) of the foreign body associated infections \[[@CR9], [@CR10], [@CR21], [@CR23], [@CR24], [@CR29], [@CR30], [@CR38], [@CR43], [@CR45], [@CR47]\].

Five patients died: a premature patient with pneumonia who was treated with antibiotics without in vitro activity against *O. xanthineolytica*, 2 patients with CVC-related bacteremia, and 2 patients with non-operated IE. According to this review, the consideration of *Cellulosimicrobium* as a relatively avirulent bacteria \[[@CR19], [@CR34]\] is only true in localized infections. The mortality rate in patients with disseminated infection, particularly in patients with IE, is high. Of the 4 previous cases with IE, 2 patients treated without cardiac surgery died and the 2 patients who underwent valve surgery survived. In our patient, surgical replacement was not considered adequate due to family rejection, and also due to comorbidity and advanced age. However, the data seem to indicate that surgical treatment of IE caused by *Cellulosimicrobium* species is necessary for cure, placing it among the infecting organisms with indication of IE surgery.

Following the updated taxonomy, the identified species in the cases reviewed was *C. cellulans* in 32 (74%) cases and *C. funkei* in 7 (16%) cases. Species identification was not reached in 4 cases. We did not find correlation between the site of infection, baseline characteristics of patients, response to treatment, outcome, and the infecting species. As Table [2](#Tab2){ref-type="table"} shows the identified susceptibility of both species to vancomycin was 100%. *C. funkei* was more susceptible than *C. cellulans* to gentamicin (100% vs. 11%), whereas *C. cellulans* was more susceptible than *C. funkei* to trimethoprim-sulfamethoxazole (93% vs. 50%). No differences in susceptibility to imipenem were detected between the two species in the reviewed cases. Brown et al. \[[@CR8]\] reported that the two *Cellulosimicrobium* species were resistant to aminoglycosides. Among its main phenotypic differences, they found that *C. funkei*, unlike *C. cellulans*, was susceptible to imipenem and resistant to trimethoprim-sulfamethoxazole. In this review, we found that *C. funkei*, unlike *C. cellulans*, was susceptible to gentamicin and that there were no significant differences in imipenem susceptibility between both species. It has already been suggested previously that susceptibility to imipenem might not be different between both species \[[@CR21]\], and according to this review, susceptibility to aminoglycosides may be a reliable phenotypic test for differentiating *C. funkei* from *C. cellulans*.

In conclusion, the uncommon *Cellulosimicrobium* infection usually occurs in immunocompromised hosts or in patients with medical devices or foreign bodies that compromise the integrity of defensive mechanisms. The most frequent pattern of *Cellulosimicrobium* infection is CVC-related bacteremia. The optimal treatment should include the withdrawal of the foreign body. If this is not possible, vancomycin should probably be part of the antibiotic regimen. Valve surgery should be considered in native or prosthetic *Cellulosimicrobium* IE because it probably improves the outcome. We should be aware of this opportunistic pathogen, as it is likely that there will be an increase in its prevalence, related to the high survival rate of immunocompromised patients, the increasing use of long-term medical devices, and the advances in microbiological diagnostic techniques.

CVC

:   Central venous catheter

IE

:   Infective endocarditis;

MALDI-TOF MS

:   Matrix-assisted laser desorption ionization-time of flight mass spectrometry

MIC

:   Minimum inhibitory concentration
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